Sildenafil Citrate Tablet
Product Images NDC 72603-883

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72603-883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil Citrate Tablets 100 mg (NDC 72603-885-02)

Label for Sildenafil Tablets USP 100 mg oral tablets, supplied in a package of 100 tablets. The label indicates the product is Rx only, manufactured by Umedica Laboratories Pvt. Ltd. in India for Northstar Rx LLC, Memphis, TN. It includes storage instructions, dosage reference, and a barcode.*

FDA Label Image

Sildenafil Citrate Tablets 100 mg (NDC 72603-885-01)

Label for Sildenafil Tablets, USP 100 mg by Northstar Rx LLC. The package contains 30 tablets. It includes storage instructions (store at 25°C with excursions permitted between 15-30°C) and notes that the package is child-resistant. Manufactured by Umedica Laboratories Pvt. Ltd. in India and labeled for Northstar Rx LLC in Memphis, TN.*

FDA Label Image

Sildenafil Citrate Tablets 25 mg (NDC 72603-883-01)

Sildenafil Tablets USP 25 mg in a 30-tablet bottle label. The label shows the product name, strength, quantity, and storage instructions. It is manufactured by Umedica Laboratories Pvt. Ltd., India, and labeled by Northstar Rx LLC, Memphis, TN. The label includes an NDC 72603-883-01 and barcode.*

FDA Label Image

Sildenafil Citrate Tablets 50 mg (NDC 72603-884-01)

Sildenafil Tablets USP 50 mg tablet bottle label from Northstar Rx LLC. The label states 30 tablets per container, includes storage instructions at 25°C with permitted excursions, and notes the product is manufactured by Umedica Laboratories Pvt. Ltd., India for Northstar Rx LLC. The NDC number 72603-884-01 is visible.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

A line graph comparing systolic blood pressure (mmHg) over 24 hours after dosing for Sildenafil 100 mg and placebo. The x-axis represents time post dose (hours) from pre-dose to 24 hours, and the y-axis shows changes in systolic blood pressure. The graph displays two distinct lines, one for Sildenafil and one for placebo, illustrating blood pressure variations over time.*

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

A line chart depicting the change in systolic blood pressure (SBP) in mmHg over time in hours postdose, comparing two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg. The vertical axis represents SBP change, ranging from -40 to 20 mmHg, and the horizontal axis spans 0 to 8 hours postdose. Data points are shown with lines connecting them for each treatment group.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

A line graph comparing change in systolic blood pressure (SBP) in mmHg over time postdose (hours) between two treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg. The graph shows differences in SBP changes from 0 to 8 hours postdose for both combinations.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

A line graph showing changes in mmHg over time (hours) after dosing comparing Doxazosin with Sildenafil 100 mg versus Doxazosin with Placebo. The x-axis represents time after dosing (0 to 8 hours), and the y-axis shows mmHg values ranging from -50 to 40. Two lines represent the two treatments, illustrating blood pressure changes post-dose.*

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

A line graph depicting plasma concentrations of a commercial sildenafil citrate tablet over 24 hours post-dose. The x-axis represents time in hours, and the y-axis shows plasma concentration in ng/ml. Concentrations peak around 1-2 hours and decline steadily thereafter.*

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

Two bar graphs depicting the effect of sildenafil citrate and placebo on maintenance of erection by baseline score. The vertical axis shows the percentage of patients at endpoint, and the horizontal axis shows baseline scores from 0 to 5. Bars represent different score categories as shown in the legend. The top graph shows data for sildenafil citrate, and the bottom graph shows data for placebo.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

A bar chart showing the percentage of patients reporting improvement in different treatment groups for Sildenafil citrate. The groups include Placebo (24%, n=463), Sildenafil citrate 25 mg (63%, n=214), Sildenafil citrate 50 mg (74%, n=391), and Sildenafil citrate 100 mg (82%, n=380). The chart indicates an overall treatment p-value of less than 0.0001.*

FDA Label Image

Sildenafil-citrate-structure (Sildenafil Citrate Structure)

Chemical structure diagram of sildenafil citrate, showing the molecular arrangement including heterocyclic rings, sulfonyl group, and citrate moiety as depicted in the image.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.